Kiora Pharmaceuticals (NASDAQ:KPRX) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Kiora Pharmaceuticals (NASDAQ:KPRX) issued its earnings results on Thursday. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.10, FiscalAI reports. The business had revenue of $1.00 million during the quarter.

Kiora Pharmaceuticals Trading Down 1.5%

Shares of NASDAQ:KPRX traded down $0.02 during trading on Thursday, reaching $1.33. 20,641 shares of the company traded hands, compared to its average volume of 64,861. Kiora Pharmaceuticals has a 52-week low of $1.33 and a 52-week high of $2.91. The firm has a market capitalization of $5.88 million, a price-to-earnings ratio of -0.53 and a beta of -0.13. The business’s fifty day moving average is $2.31 and its 200-day moving average is $2.38.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kiora Pharmaceuticals in a research note on Monday, October 12th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing therapies for diseases of the eye. The company’s research programs are aimed at addressing conditions with limited treatment options, including inherited retinal diseases and inflammatory eye disorders. Kiora’s lead program, KIO-301, is an investigational small-molecule therapy designed to function as a molecular photoswitch. The company is studying its potential to restore light perception in patients with vision loss caused by retinal degeneration, including retinitis pigmentosa.